Fig. 1From: Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutationsKaplan-Meier analysis for PFS in patients treated with gefitinib or erlotinib. a All patients in this study. b Patients who had brain metastasis before EGFR-TKI administration. c Patients who had no brain metastasis before EGFR-TKI administrationBack to article page